Epoetin alfa use in patients with ESRD: An analysis of recent US prescribing patterns and hemoglobin outcomes

被引:69
作者
Collins, AJ
Brenner, RM
Ofman, JJ
Chi, EM
Stuccio-White, N
Krishnan, M
Solid, C
Ofsthun, NJ
Lazarus, JM
机构
[1] Fresenius Med Care N Amer, Ledgemont Ctr 2, Lexington, MA 02420 USA
[2] Amgen Inc, Thousand Oaks, CA 91320 USA
[3] Minneapolis Med Res Fdn Inc, Chron Dis Res Grp, Minneapolis, MN USA
[4] Univ Minnesota, Minneapolis, MN USA
关键词
anemia; hemodialysis (HD); end-stage renal disease (ESRD); epoetin alfa; erythropoietin; hemoglobin; Medicare; reimbursement;
D O I
10.1053/j.ajkd.2005.05.018
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: It is unknown to what degree physicians adjust erythropoietin doses to achieve hemoglobin levels (11.0 to 12.0 g/dL [110 to 120 g/L]) recommended by the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI) for patients with end-stage renal disease receiving hemodialysis. Our objective is to examine epoetin alfa prescribing patterns for achieving the target hemoglobin level range in this population. Methods: Monthly hemoglobin levels and epoetin alfa doses from 2 large databases were retrospectively analyzed. One data set comprised 31,267 patients from the Fresenius Medical Care-North America (FMC-NA) database, and the other comprised 128,761 patients based on claims for Medicare services. Results: Longitudinal evaluation of the FMC-NA data set showed that hemoglobin levels in patients administered epoetin alfa cycled in and out of the NKF-K/DOQI hemoglobin target range, and doses were decreased in 98.8% of patients with persistent hemoglobin levels greater than 12.0 g/dL (> 120 g/L). Hemoglobin levels in patients from the Medicare data set that initially were outside the target range migrated into the range with epoetin alfa dose titration. FMC-NA patients with a 3-month average hemoglobin level less than 11.0 g/dL (<110 g/L) were administered significantly greater epoetin alfa doses than those with average hemoglobin levels greater than 12.0 g/dL (> 120 g/L; 21,838 versus 13,503 U/wk; P < 0.0001). Less than 0.4% of patients administered epoetin alfa were persistently anemic (hemoglobin < 11.0 g/dL [< 110 g/L]) and were administered persistently high doses (>30,000 U/wk), but failed to respond with a 0.5-g/dL or greater (>= 5-g/L) increase in hemoglobin levels. Conclusion: In these analyses, few hemodialysis patients experienced persistent anemia while being administered high epoetin alfa doses. Physicians appeared to appropriately adjust doses to achieve hemoglobin levels recommended by the NKF-K/DOQI guidelines.
引用
收藏
页码:481 / 488
页数:8
相关论文
共 33 条
[1]  
[Anonymous], 2001, Am J Kidney Dis, V37, pS182
[2]   Association of kidney function with anemia - The Third National Health and Nutrition Examination Survey (1988-1994) [J].
Astor, BC ;
Muntner, P ;
Levin, A ;
Eustace, JA ;
Coresh, J .
ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (12) :1401-1408
[3]   Hemoglobin variability in epoetin-treated hemodialysis patients [J].
Berns, JS ;
Elzein, H ;
Lynn, RI ;
Fishbane, S ;
Meisels, IS ;
DeOreo, PB .
KIDNEY INTERNATIONAL, 2003, 64 (04) :1514-1521
[4]   IMPROVED PHYSICAL PERFORMANCE AFTER TREATMENT OF RENAL ANEMIA WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN [J].
BRAUMANN, KM ;
NONNASTDANIEL, B ;
BONING, D ;
BOCKER, A ;
FREI, U .
NEPHRON, 1991, 58 (02) :129-134
[5]  
Centers for Medicare & Medicaid Services, 2003, 2003 ANN REP END STA
[6]   United states renal data system assessment of the impact of the national kidney foundation-dialysis outcomes quality initiative guidelines [J].
Collins, AJ ;
Roberts, TL ;
Peter, WLS ;
Chen, SC ;
Ebben, J ;
Constantini, E .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (04) :784-795
[7]  
Collins AJ, 2001, J AM SOC NEPHROL, V12, P2465, DOI 10.1681/ASN.V12112465
[8]   Anaemia of critical illness - implications for understanding and treating rHuEPO resistance [J].
Eckardt, KU .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2002, 17 :48-55
[9]   K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification - Foreword [J].
Eknoyan, G ;
Levin, NW .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (02) :S14-S266
[10]   RECOMBINANT HUMAN ERYTHROPOIETIN IN ANEMIC PATIENTS WITH END-STAGE RENAL-DISEASE - RESULTS OF A PHASE-III MULTICENTER CLINICAL-TRIAL [J].
ESCHBACH, JW ;
ABDULHADI, MH ;
BROWNE, JK ;
DELANO, BG ;
DOWNING, MR ;
EGRIE, JC ;
EVANS, RW ;
FRIEDMAN, EA ;
GRABER, SE ;
HALEY, NR ;
KORBET, S ;
KRANTZ, SB ;
LUNDIN, AP ;
NISSENSON, AR ;
OGDEN, DA ;
PAGANINI, EP ;
RADER, B ;
RUTSKY, EA ;
STIVELMAN, J ;
STONE, WJ ;
TESCHAN, P ;
VANSTONE, JC ;
VANWYCK, DB ;
ZUCKERMAN, K ;
ADAMSON, JW .
ANNALS OF INTERNAL MEDICINE, 1989, 111 (12) :992-1000